Related Experiment Video
Updated: Aug 9, 2026
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 31, 2013
Interferon-mediated in vivo induction of beta 2-microglobulin on small-cell lung cancers and mid-gut carcinoids
Abstract:
Selected neuroendocrine tumors, such as small cell lung cancer (SCLC), and neuroblastoma express markedly diminished class I major histocompatibility complex (MHC) antigens (HLA framework and beta 2-microglobulin, beta 2m). Another neuroendocrine tumor, mid-gut carcinoid, also expresses reduced beta 2m antigen as demonstrated herein. Antigen expression is greatly enhanced on SCLC cell lines by in vitro exposure to interferon (IFN). To determine whether IFN mediates similar effects in vivo, we examined by immunoperoxidase staining beta 2m expression in paraffin-embedded tumor tissue sections obtained from 4 SCLC and 7 mid-gut carcinoid patients before and after receiving partially purified human leukocyte IFN-alpha therapy. Before IFN treatment, 3/4 SCLC tumors and 5/7 mid-gut carcinoids did not express beta 2m. By contrast, all tumors showed considerable expression of beta 2m after IFN therapy. Induction of class I antigens on tumor cells deficient in such expression may be one mechanism by which IFN exerts antitumor effects. We believe this is the first report of in vivo induction of class I MHC antigens in epithelial tumor cells in humans.
Insights
Interferon (IFN) therapy can restore diminished beta 2-microglobulin (beta 2m) expression in neuroendocrine tumors like small cell lung cancer (SCLC). This study shows IFN
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Selected neuroendocrine tumors, including small cell lung cancer (SCLC) and neuroblastoma, exhibit significantly reduced expression of class I major histocompatibility complex (MHC) antigens.
- Reduced beta 2-microglobulin (beta 2m) expression is a characteristic feature observed in these tumor types, potentially impacting immune recognition.
- In vitro studies demonstrated that interferon (IFN) enhances antigen expression on SCLC cell lines.
Purpose of the Study:
- To investigate whether interferon (IFN) can induce class I MHC antigen expression in vivo in patients with neuroendocrine tumors.
- To assess the effect of human leukocyte IFN-alpha therapy on beta 2m expression in SCLC and mid-gut carcinoid tumors.
Main Methods:
- Immunoperoxidase staining was used to analyze beta 2m expression.
- Paraffin-embedded tumor tissue sections from SCLC and mid-gut carcinoid patients were examined before and after IFN-alpha therapy.
- Analysis included 4 SCLC patients and 7 mid-gut carcinoid patients.
Main Results:
- Prior to IFN treatment, a majority of SCLC (3/4) and mid-gut carcinoid (5/7) tumors showed no detectable beta 2m expression.
- Following IFN-alpha therapy, all examined tumors (SCLC and mid-gut carcinoid) exhibited significant beta 2m expression.
- This indicates a substantial induction of class I MHC antigens in tumor cells after in vivo IFN treatment.
Conclusions:
- Interferon (IFN) therapy can effectively induce the expression of class I MHC antigens in epithelial tumor cells in vivo.
- Restoring antigen expression on tumors deficient in such molecules may represent a key mechanism for IFN's antitumor effects.
- This study provides the first report of in vivo induction of class I MHC antigens in human epithelial tumor cells.
